|Bid||2.10 x 100|
|Ask||2.35 x 100|
|Day's range||2.28 - 2.35|
|52-week range||0.22 - 6.06|
|PE ratio (TTM)||N/A|
|Earnings date||18 May 2017 - 19 May 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.00|
Celsion's (CLSN) plan for phase I/II study to evaluate DNA-based immunotherapy, GEN-1, in ovarian cancer gets FDA approval and clearance for initiation.
Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling
Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.
Celsion's (CLSN) pipeline candidate, GEN1, controls ovarian cancer in all patients in the phase Ib study and achieves a historical improvement in progression free survival.